Objective -To determine the feasibility of a randomised trial of ovarian cancer screening among women attending a breast cancer screening centre. Design -Randomised controlled trial of ovarian cancer screening using transvaginal ultrasonography as a primary screening test and colour Doppler imaging as a secondary screening test in the screened group and no intervention in the control group. Setting -Reading breast cancer screening centre (United Kingdom). Subjects -8678 women, without a bilateral oophorectomy or hysterectomy, aged between 50 and 64 attending for NUS breast cancer screening between September 1989 and February 1993. Main outcome measures -Uptake of ovarian cancer screening among eligible women and the screening false positive rate (considered as the referral rate to a gynaecologist for surgical intervention). Results-82% (7124/8678) ofeligible women agreed to join the trial and were randomly allocated in equal numbers to each arm of the trial. 3280 women had an initial scan. The false positive rate after ultrasonography alone was 2·9% (86/2952), but this dropped to O' 5% after colour Doppler as a secondary screening test. One stage I primary ovarian cancer was detected at screening in a 58 year old women. Conclusions -A randomised trial of ovarian cancer screening using ultrasonography and colour Doppler imaging is feasible and acceptable among women attending a breast cancer screening centre. The results indicate that the expected odds of being affected given a positive result in the general population would be about 1:12. A full randomised trial ofovarian cancer screening with mortality as the end point is needed to assess whether screening reduces mortality from this disease. A multicentre European trial is currently in progress.
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(Journal of Medical Screening 1994;1: [209] [210] [211] [212] [213] [214] Ovarian cancer is the most common gynaecological cancer, with 5200 new cases and 3900 deaths (6% of all female cancer deaths) in England and Wales each year. I 2 The potential for screening is high because survival is greatly dependent on the stage of the cancer at diagnosis. The overall five year survival rate is only about 30%. In women with a localised tumour (stage I) at the time of diagnosis it is about 75%/-5 or in recent American data 96%. 6 Ovarian cancer is associated with enlargement of the affected ovary and changes in its shape and structure. These changes can often be reflected in ultrasound findings," and ultrasonography can detect early stage ovarian cancer in asymptomatic women.P" However, early detection alone is insufficient to satisfy the requirements for a worthwhile cancer screening procedure. It is also necessary to know whether screening reduces mortality from ovarian cancer, a question that can only be reliably answered by a randomised controlled trial. Conducting such a trial is a major undertaking, but without it ovarian cancer screening is likely to be incorporated piecemeal into clinical practice without evidence of efficacy.
The potential benefit of screening for ovarian cancer and the uncertainty about its efficacy prompted us to carry out a pilot study to determine the feasibility and acceptability of a randomised trial of ovarian cancer screening. This trial, launched in 1989, was conducted among women attending the Reading screening centre as part of the NHS breast screening programme. The feasibility study at Reading did not aim at measuring the detection rates of the screening tests (to do this many more women would have to be included and results of follow up would be needed). It aimed at discovering if screening was feasible in a breast screening setting by assessing its acceptability to the women and determining whether the false positive rate of the screening tests was sufficiently low. 
Patients and methods

PATIENTS
We recruited women attending the Reading screening centre for mammographic breast cancer screening. All women aged 50-64 were eligible for the trial except those who had had a bilateral oophorectomy or hysterectomy as the risk of ovarian cancer is about 25% lower in women who have had a hysterectomy.l'"!" Consent to participate was sought after the woman had read a leaflet describing the trial.
TRIAL DESIGN AND SCREENING PROCEDURE
Women who agreed to take part in the trial were allocated at random to two groups: a screened group offered ultrasound scanning of the ovaries every three years when they attended for breast screening, and a control group that was not screened.
Initially, the screening procedure consisted of a transvaginal ultrasound scan at the first screening visit, followed six weeks later by a review scan if the initial scan was positive, as defined below. Scans were performed on an Aloka 500 machine with a 5·0 MHz vaginal probe. A six week interval was used between scans to allow for cyclical changes in the ovaries of premenopausal women. If the review scan remained positive the woman was considered screen positive and referred to a designated 'consultant gynaecologist for laparotomy. If the initial scan was negative the woman was considered screen negative and asked to return for a repeat screen in three years. The three year screening interval was chosen to coincide with the interval used for breast cancer screening. and were eligible for an invitation for a routine recall screening examination after three years.
CUT OFF LEVELS AND DEFINITION OF A POSITIVE TEST
The ultrasound scan was considered positive if the volume of the larger of the two ovaries was greater than four times the median volume in premenopausal women of the same age (that is, four multiples of the normal median), or three times the median volume in postmenopausal women of the same age (that is, three multiples of the normal median). Postmenopausal women were defined as those women who had not had a period in the past 12 months. The cut off levels were originally chosen so that they corresponded to the upper 96th centile of volume for women in each group. In the King's College Hospital study" all the five cancers detected (all stage I) were above the 96th centile. In our study initially, examinations were carried out using transabdominal ultrasound. This required a full bladder, which was inconvenient. Transabdominal and vaginal scan results were compared in 309 women who were examined by both methods. There was high correlation (r= 0'97) between the two methods in their estimates of ovarian volume (fig 3) , and vaginal ultrasound was well accepted by the women, so vaginal ultrasound was subsequently used routinely.
Ovarian volume was found to decrease with age. The relation between the median ovarian volume of the larger ovary and age was summarised for both premenopausal and postmenopausal women by a log linear regression of median ovary size on age weighted by the number of women in each year of age. Figure  4 shows the regressions on 912 premenopausal and 1783 postmenopausal women, all scanned by the same ultrasonographer. Within the age range studied (50-64 years) ovarian volume was negatively associated with age in both premenopausal (P<0'005) and postmenopausal women (P<0'05); the magnitude of the association was greater in premenopausal women.
Of the 912 women categorised as premenopausal, 371 (41 %) were taking hormone replacement therapy (presumably because of perimenopausal symptoms). Only 36 (2%) of the 1783 postmenopausal women were taking hormone replacement therapy. Figure 5 shows that premenopausal women receiving hormone replacement therapy had a less pronounced fall in ovarian volume with increasing age than those not receiving it (P<0·05). Towards the end of the feasibility study we incorporated this finding in the cut off definitions by using two sets of medians to calculate cut off levels for premenopausal women, and maintaining a positive test result at four or more multiples of the normal median for both.
A positive colour Doppler result was defined by the presence of a low impedance (pulsatility index < 1'0) high velocity blood flow (peak systolic velocity > 10 cm/s) from an area of morphological abnormality. 10 During the study the high initial false positive rate was a concern, and it subsequently emerged that the use of colour Doppler ultrasound scanning as a secondary screening test for ovarian cancer among screen positive women could reduce this rate. [15] [16] [17] Colour Doppler imaging detects angiogenesis in the ovary. New vessel growth is a feature of ovarian malignant tumours, and the colour Doppler imaging visualises the blood flow within these vessels. Eight months after the launch of the feasibility study, colour Doppler ultrasound scanning was incorporated as a secondary screening test. Women who had two positive ultrasound scans were referred to King's Col- 
Discussion
Our results showed that a randomised trial of ovarian cancer screening using transvaginal ultrasound examination of the ovaries is feasible. The uptake among women attending a breast cancer screening centre is high -82%.
Transvaginal ultrasound was acceptable to the women, and it was preferable to abdominal scanning because women could be scanned without a full bladder, which is necessary with transabdominal scanning. Measurements on
Results
Of the 8678 eligible women invited tb join the trial, 7124 (82%) agreed to participate and were allocated at random to each arm of the trial. Eight per cent (282/3562) of women in the screening arm subsequently declined to have a scan. Table 1 summarises the screening results of the study. In total, 3280 women had an initial scan: 2881 a transvaginal scan and 399 a transabdominal scan. The ovaries were visible in 2513 (87%) of women transvaginally and in 395 (99%) women transabdominally.
Three hundred and twenty seven women had an initial scan during the first phase of the trial before colour Doppler imaging had been introduced as a secondary screening test, and 2953 women had an initial scan during the second phase of the trial after its introduction.
One interval cancer (stage I malignant clear cell carcinoma of the ovary) occurred in a 56 year old screen negative premenopausal woman, 19 months after a normal transvaginal scan performed in the first phase of the trial.
After colour Doppler ultrasound was introduced as a secondary screening test, the false positive rate (estimated from the positive rate less the detected ovary cancer) after ultrasonography alone was 2·9% (86/2952). The overall false positive rate after colour Doppler imaging dropped to 0'5% (14/2952) if considered as the referral rate to a gynaecologist, or 0·3% (9/2952) if considered as the surgical intervention (laparotomy or laparoscopy) rate.
Of the 15 women who were referred to a gynaecologist in the second phase of the study, there were 14 false positives and one true positive who had a stage I malignant ovarian tumour. She had not had a colour Doppler examination because she was referred directly to the gynaecologist. The reason for this deviation from the protocol was that the ultrasound scan on this patient showed such abnormal morphology in the affected ovary that an urgent referral was felt necessary, without waiting for a colour Doppler examination.
For the 14 false positives, nine had surgery (seven laparotomies and two laparoscopies) and were found to have either non-neoplastic cysts (six patients) or benign tumours (three). Of the five remaining false positives four had a cyst aspiration with no evidence of malignant cells and one was followed up with repeat ultrasound scans in the outpatient department. No malignancy was found at operation in any of the 10 women referred for surgery outside the study protocol. t Seven laparoromies and two laparoscopies: the remaining five women referred ro a gynaecologist had either cyst aspiration under ultrasound (four women) or were followed up in the clinic (one).
:j:This is the number among women following the study protocol. Some women were referred to a gynaecologist for reasons not specified in the study protocol. If these are included the rate is 0·8% (25/2952). § This is the number for women following the study protocol. The toral rare in practice was 0'6% (J 9/2952). transvaginal and transabdominal scanning were highly correlated, though the visualisation rate for transvaginal scanning was less than that for transabdominal. Because of this it would seem worthwhile repeating the ultrasound examination transabdominally in women whose ovaries are not visualised transvaginally.
The use of multiples of the median to specify screening cut off levels was adopted from experience gained in antenatal screening for neural tube defects." A positive ovarian ultrasound scan can be defined using multiples of the median ovarian volume for a woman's age and menopausal status, thereby allowing for the reduction in size of the ovaries after the menopause and with increasing age.
The observed detection rate for primary ovarian cancer for this screening method is 100% in the reported studies to date among healthy volunteers from the general population.!? though this estimate was based on only seven cases. In screening the false positive rate needs to be low enough to ensure acceptably high odds of being affected given a positive result (OAPR). The false positive rate at the first screen in the King's College Hospital study of transabdominal ultrasound screening among the general population was 3'5%, but the relative rarity ofthe disorder meant that the OAPR was only 1:97. 8 Our study showed that the false positive rate using colour Doppler imaging as a secondary screening test was reduced from 2·9% to 0·5% and, correspondingly, the number of women referred for diagnostic surgery was reduced. This rate is acceptably low for a screening programme.
An additional 11 women in the study were either self referred or referred by their general practitioner to a gynaecologist for reasons out- side those specified in the protocol. The effect of this is to increase the false positive rate from 0·5% to 0'8%, and this shows the importance in any screening programme of having clearly defined definitions of positives and referral criteria.
Our study had insufficient power to assess the effect of colour Doppler imaging on the detection rate of early ovarian cancer, but data from the King's study of familial ovarian cancer" suggest that this would not be reduced to any material extent with screening intervals of two years or less. If the prevalence of primary ovarian cancer were 1 in 2500 (which is approximated to the incidence rate" because the median duration of survival for ovarian cancer is short (about 1·6 ·years)) then the OAPR for screen positive women would be about 1:12high enough to justify a diagnostic laparotomy.
It is now necessary to find out whether ovarian cancer screening reduces mortality from this disease. Estimates can be made of the expected effect screening may have on mortality if the change in the stage distribution at screening is reflected in changes in mortality. If the proportion of cancers diagnosed at stage I (localised disease) increased and the currently observed five year survival rate for stage I disease were applied to the increased proportion diagnosed then the expected decrease in deaths can be calculated (table 2) . Data on the stage distribution and survival were from the USA and Norway.l" If screening increased the proportion of patients with localised tumours at diagnosis to 80% instead of the observed 34% then there would be an estimated 43% reduction in mortality. The largest reduction in mortality that screening could achieve would be 61 % if all tumours were diagnosed when still localised.
In the two screening studies reported among asymptomatic women'" all the seven primary ovarian cancers detected were stage I. It is likely that in practice the proportion oflocalised cancers would be less than 100%, say, 80%. In 1992 in England and Wales there were 3900 deaths from ovarian cancer'; 1155 (30%) of these were among women aged 50-64. If screening women aged 50-64 reduced mortality by 43 %, and if the main effect on mortality were on women aged 55-69, then about 640 deaths from ovarian cancer would be prevented each year. This is about half the number of lives expected to be saved from the current • Based on mortaliry in 1992' for ovary and breast and 1974' for cervix (that is, before screening began to have an effect on cervical cancer mortality).
t Assuming reduction in mortality of 43% for ovarian cancer, 31 % for breast cancer, and 91 % for cervical cancer.
*Estimated average cost per basic screen. § Assuming all women aged 50-64 (for ovarian and breast cancer) and 25-64 (for cervical cancer) are screened once over a three
year period (female population in England and Wales in 1991 aged 50-64 = 3962·7 x 10' and aged 25-64 = 13 109·0 x 10'). II Assuming average life expectancy is 19·3 years for women dying of ovarian cancer, 19·5 years for women dying of breast cancer, and 25·1 years for women dying of cervical cancer.
breast cancer screening programme, on the basis of a 31 % reduction in mortality derived from the published randomised trials in breast screening." Table 3 shows the estimated cost effectiveness of ovarian cancer screening, compared with breast and cervical cancer screening. The costs per year of life saved would be £2100 for ovarian cancer screening, £1100 for breast, and £2200 for cervix (using life expectancy estimates from English life tables"). Ovarian cancer screening is likely to be less expensive than cervical cancer screening but more expensive than breast cancer screening. If screening for all three were combined there would be savings, increasing the cost effectiveness of each.
A multicentre trial is now under way -the European randomised trial of ovarian cancer screening (ERTOCS).
